Rapid antidepressant response with ketamine: Is it the solution to resistant depression

Indian Journal of Psychological Medicine

Volumn 34, Issue 1, 2012, Pages 56-60

  Thakurta, Rajarshi Guha ^a   Ray, Paramita ^a   Kanji, Dipankar ^a   Das, Ranjan ^a   Bisui, Bikash ^a   Singh, Om Prakash ^a  

^a BURDWAN MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Glutamate; ill sustained; ketamine; treatment resistant depression

Indexed keywords

EID: 84861313198     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.96161     Document Type: Article

References (27)

1. WHO. The World Health Report 2001-Mental Health: New Understanding, New Hope. World Health Organization. Geneva: World Health Organization; 2001.
2. Mathew SJ. Treatment-resistant depression: Recent developments and future directions. Depress Anxiety 2008;25:989-92.
3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40.
4. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:338-43.
5. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7.
6. Hyman SE, Nestler EJ. Initiation and adaptation: A paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151-62.
7. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426-37.
8. Harrison NL, Simmonds MA. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 1985;84:381-91.
9. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-54.
10. Sackeim HA. The definition and meaning of treatmentresistant depression. J Clin Psychiatry 2001;62 Suppl 16:10-7.
11. First MB, Spitzer RL, Gibbon M, Williams AR. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, Biometrics Research; 2001.
12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
13. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
14. Snaith RP. Hamilton rating scale for depression. Br J Psychiatry 1977;131:431-2.
15. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-5.
16. Wirz-Justice A, Van den Hoofdakker RH. Sleep deprivation in epression: What do we know, where do we go? Biol Psychiatry 1999;46:445-53.
17. Husain MM, Rush AJ, Fink M, Knapp R, Petrides G, Rummans T, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): A Consortium for Research in ECT (CORE) report. J Clin Psychiatry 2004;65:485-91.
18. Marangell LB, George MS, Callahan AM, Ketter TA, Pazzaglia PJ, L'Herrou TA, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 1997;54:214-22.
19. DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: A double-blind, placebocontrolled study. Am J Psychiatry 2000;157:1334-7.
20. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-77.
21. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, et al. Remission rates following antidepressant therapy with bu-propion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974-81.
22. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64.
23. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist. Biol Psychiatry 2009;65:181-4.
24. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-7.
25. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349-52.
26. White PF, Schuttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. Comparative pharmacology of the ketamine isomers: Studies in volunteers. Br J Anaesth 1985;57:197-203.
27. Rao TS, Andrade C. Innovative approaches to treatmentrefractory depression: The ketamine story. Indian J Psychiatry 2010;52:97-9.